ClinicalTrials.gg
CompletedNCT05913076Updated Jun 22, 2023

Class III Malocclusion and ALT-RAMEC

An interventional study of Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group and Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group in Face Mask, Rapid Maxillary Expansion and Maxillary Retrognathism, sponsored by Trakya University. Completed at 1 site in Turkey. Open to participants aged 9 Years to 11 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-06-22.

Sponsored by Trakya University · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 11 years 4 months after the study started (first participant enrolled Jan 2012, registered May 2023).
Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Randomized
Ages
9 Years to 11 Years
Sex
All
01

Study summary

Diverse viewpoints exist regarding the correlation between the conventional rapid maxillary expansion (RME) and facemask approach and the alternative RME and facemask hybrid technique (Alt-RAMEC) in terms of the degree of maxillary protraction. The findings of the study may offer a novel approach to protocol selection based on the anomaly's degree of severity. The objective of this investigation is to assess and contrast the skeletal and dentoalveolar outcomes of three distinct Alt-RAMEC techniques.

Read the detailed description

Alternating rapid maxillary expansion and constriction (Alt-RAMEC) procedure is one of the most frequently used methods in the treatment of Class III cases caused by maxillary retrognathia. The objective of this investigation is to conduct a comparative analysis of the skeletal and dentofacial outcomes of three distinct techniques for maxillary protraction Following the primary recording, the patients were evaluated using bonded-type rapid maxillary expansion (RME) devices and three discrete Alt-RAMEC techniques (1, 3, and 5 weeks). Lateral cephalograms were obtained from a sample of 40 patients (18 males and 22 females) with a mean age of 10.64 ± 0.98. These images were taken both before (T1) and after the 6th month of facemask treatment (T2), and were subjected to total and local superimpositions. The Wilcoxon Sign, Kruskal-Wallis and Mann-Whitney U tests were used to evaluate the data.

02

Conditions studied

  • Face Mask
  • Rapid Maxillary Expansion
  • Maxillary Retrognathism

Browse trials for

03

In context

Retrognathia

62 studies on the registry are indexed under Retrognathia; 15 are open to participants now.

This study's enrollment of 40 is above the median of 34 across 52 interventional studies indexed under Retrognathia.

Browse Retrognathia studies →

Lead sponsor

Trakya University is the lead sponsor of 155 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
9 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Maxillary retrognathia (SNA ≤ 79°)
  • Skeletal Class III malocclusion (ANB ≤ -1°)
  • Anterior cross-bite
  • Class III molar relationship
  • Horizontal growth pattern (SN/Go-Gn \< 30°)

Exclusion criteria

Exclusion Criteria:

  • Previous orthodontic treatment
  • Systemic disorders
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
40 participants (actual)

Study arms

  • Experimental
    Investigation of the Effects of Alt-RAMEC and Facemask 1 week Use in Class III Malocclusion

    A sample of 40 patients, consisting of 18 males and 22 females with a mean age of 10.64 ± 0.98, who were in the growth and developmental stage, were divided into three treatment groups. The formation of groups was carried out with the aim of achieving a near-equal distribution of male and female participants within each group, as indicated in Table 1. The first group comprised 14 patients, while the second and third groups consisted of 13 patients each. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.

    Device: Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group

  • Experimental
    Investigation of the Effects of Alt-RAMEC and Facemask 3 week Use in Class III Malocclusion

    The second group comprised 13 patients who were in the growth and developmental stage. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.

    Device: Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group

  • Experimental
    Investigation of the Effects of Alt-RAMEC and Facemask 5 week Use in Class III Malocclusion

    The third group comprised 13 patients who were in the growth and developmental stage. The skeletal age of the individual was determined through the acquisition of hand-wrist X-rays and the application of the Greulich and Pyle atlas at T1.

    Device: Delaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group

Interventions

  • DeviceDelaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for first group

    The study involved the fabrication of occlusal-coverage bonded type RME devices utilizing Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy). Each patient in Group 1 (classical RME method) was instructed to open Hyrax screw twice a day for a week. At the end of the respective periods (1 week), the screws were fixed with ligatures, and the patients were evaluated. Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months.

    Also known as: (Fabricated for every patient) Bonded-type Expansion Device

  • DeviceDelaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for second group

    The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 2. Each patient in Group 2 (3-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. At the end of the respective periods (3 weeks), the screws were fixed with ligatures, and the patients were evaluated. Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months.

    Also known as: (Fabricated for every patient) Bonded-type Expansion Device

  • DeviceDelaire Face Mask (M0774-01, Leone S.p.A., Florence, Italy) for third group

    The same fabrication of occlusal-coverage bonded type RME devices were utilized Hyrax screws (A0620-11, Leone S.p.A., Firenze, Italy) in Group 3. Each patient in Group 3 (5-week Alt-RAMEC protocol), the patients were instructed to activate Hyrax screw twice a day for one week, close the screw for following week, and open the screw over the third week. The aforementioned screw open-close procedure was implemented over a period of five weeks. At the end of the respective periods (5 weeks), the screws were fixed with ligatures, and the patients were evaluated. Face-mask treatment was subsequently started after RME. Totaling 700 g of extraoral traction force applied to maxilla. Patients were advised to wear Delaire type facemasks (M0774-00, Leone SpA) 14-16 hours a day for 6 months.

    Also known as: (Fabricated for every patient) Bonded-type Expansion Device

06

What researchers measure

Primary outcomes

  1. Evaluation of Skeletal, Dental, and Soft Tissue Angular Measurements

    Changes at the maxillary advancement, teeth positions and soft tissues amount were assessed in angular level. Skeletal measurements: Angular measurements: SNA (°), SNB (°), SN/S-Gn (Y-axis)(°), SN/Go-Gn (°), Ar-Go-Gn (°), SN/Go-Ar (°), and ANB (°) were measured. Dental measurements: Angular measurements: U1 to MaxP (°) for maxillary dentoalveolar measurements; L1-MandP (°) for mandibular dentoalveolar measurements; U1-L1 (°) for interdental measurements were performed. Soft tissue measurements: Changes at the upper and lower lip assessed. Angular measurements: G-Sn-Pg' (°), Nasolabial angle (°), and Labiomental angle (°) were measured.

    Time frame: 6 months

Secondary outcomes

  1. Evaluation of Skeletal, Dental, and Soft Tissue Millimetrical Measurements

    Changes at the maxillary advancement, teeth positions and soft tissues amount were assessed in millimetrical level. Skeletal measurements: Millimetrical measurements: Co-A (mm) for maxillary skeletal measurement, Co-B (mm) for mandibular skeletal measurement, N-Me (mm), N-ANS (mm), and ANS-Me (mm) for maxillomandibular skeletal measurements were performed. Dental measurements: Millimetrical measurements: U1-MaxP (mm), U1-MaxVP (mm), U6-MaxP (mm), U6-MaxVP (mm) for maxillary dentoalveolar measurements; L1-MandP (mm), L1-MandVP (mm), L6-MandP (mm), L6-MandVP (mm) for mandibular dentoalveolar measurements; Overbite (mm) and overjet (mm) for interdental measurements were performed. Soft tissue measurements: Changes at the upper and lower lip assessed. Millimetrical measurements: Ls-S (mm) and Li-S (mm) were measured.

    Time frame: 6 months

07

Study locations

1 site
  • Trakya University
    Edirne, 22000, Turkey
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 22, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05913076
Lead sponsor
Trakya University
Collaborators
Istanbul University
Responsible party
Hande Uzunçıbuk (Research Assistant Dr./ Principal Investigator, Trakya University) — Principal investigator
First posted
Jun 22, 2023
Start date
Jan 13, 2012
Primary completion
Jul 15, 2012
Completion
Aug 15, 2012
Last update
Jun 22, 2023

Study contacts

Nilüfer Yılmaz Öğütlü, Dr.
study director · Istanbul University
Gülsün Külekçi Çakan
principal investigator · Private Practitioner
Hülya Kılıçoğlu, Prof. Dr.
study chair · Istanbul University
Hande Uzunçıbuk, Dr.
principal investigator · Trakya University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion